Daphne Karydas
3 stock trades in the last 12 months, shares they bought or sold themselves (not grants or options).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Every trade Daphne Karydas reported
| Stock | Trade | Amount | Traded |
|---|---|---|---|
| Sell(10b5-1 plan) | $86K | Sep 15SEC filing | |
| Sell(10b5-1 plan) | $75K | Jun 17SEC filing | |
| Sell(10b5-1 plan) | $75K | Mar 31SEC filing |
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Daphne Karydas' companies
| Stock | Trades | Quality Score |
|---|---|---|
| 3 |
Alerts for Daphne Karydas
Use this page
How to cite
Breakaway, Daphne Karydas: Director at Mineralys Therapeutics (MLYS), Sep 17, 2026, getbreakaway.com/insiders/daphne-karydas
Journalists: email support@getbreakaway.com for the data behind this page.